Lead Product(s): Remestemcel-L
Therapeutic Area: Immunology
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2020
The data shows effectiveness of remestemcel-L in children with SR-aGVHD, with particular efficacy and survival benefit in patients with the most severe forms of aGVHD.